Supporting Information

An Insight into Tetrahydro-β-carboline-Tetrazole Hybrids: Synthesis and Bioevaluation as Potent Antileishmanial Agents

Pooja Purohit, Anand Kumar Pandey, Deepti Singh Chauhan, Pradeep Singh Chouhan, Karthik Ramalingam, Mahendra Shukla, Neena Goyal, Jawahar Lal, Prem M. S. Chauhan

aMedicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow-226031, U.P., India.
bDivision of Biochemistry, CSIR-Central Drug Research Institute, Lucknow-226031, U.P., India.
cPharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India.

*Corresponding author mailing address: Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow-226031, U.P, India, Phone: +91 522 2771940, 2771942; Fax: +91 522 2771941. Email: prem_chauhan_2000@yahoo.com; premsc58@hotmail.com

Table of content

Experimental section for Antileishmanial activity S2 – S4
Experimental section for Pharmacokinetics study S5 – S6
References S6
Spectra of compounds S7 – S27
Experimental section for antileishmanial activity: Each compound was evaluated for its *in vitro* activity against WHO reference strain (MHOM/IN/80/Dd8) of extracellular promastigotes and intramacrophagic amastigotes (expressing luciferase firefly reporter gene) of *L. donovani*. The *in vitro* cytotoxicity assay was performed using murine macrophage J-774A.1 cell line.

*In vitro* antileishmanial assay: *Leishmania donovani* promastigotes (WHO designation MHOM/IN/80/Dd8), originally obtained as a gift from (late) Prof. P. C. C. Garnham and routinely maintained at the institute in golden hamsters, were used in the present study. Promastigotes were grown in medium 199 medium (Sigma) supplemented with 10% heat-inactivated fetal calf serum (GBL) and 1% penicillin (50 U/ml) and streptomycin (50 mg/ml) solution (Sigma) at 24 °C. Luciferase tagged with promastigotes maintained at 25 ± 1 °C in medium 199 (Sigma Chemical) supplemented with 10% Fetal Calf Serum (Gibco, Gaithersburg, MD, USA) and G418 (20 μg/ml) were used for *in vitro* evaluation of antileishmanial activity.

Antipromastigote activity: The *in vitro* effect of test compounds on the growth of promastigotes was assessed by monitoring the luciferase activity of viable cells after treatment. The transgenic promastigotes of late log phase were seeded at 5 X10⁵ cells/well in 96- well flat-bottomed microtitre (MT) plates (CELLSTAR Greiner Bio-one Gmbh, Monroe, NC, USA) and incubated for 72 h in medium, in absence (control) or the presence of test compounds (stock prepared in 100% DMSO, initial concentration, followed by serial dilution in media). The test compounds were added at 2-fold dilutions in up to 7 points in fresh complete medium starting from a 100 μM concentration. After incubation, an aliquot (50 μL) of promastigote suspension was aspirated from each well of a 96-well plate and mixed with an equal volume of Steady Glo (R) reagent (Promega, Madison, WI, USA) and luminescence was measured in luminometer.
Antiamastigote activity: For assessing the activity of compounds against amastigote stage of the parasite, mouse macrophage cell line (J-774A.1), infected with promastigotes expressing firefly luciferase reporter gene was used. Macrophage cells were seeded in a 96-well plate (5 X10^4 cells / 200 µl / well) in RPMI-1640 containing 10 % fetal calf serum. The plates were incubated at 37 °C in a CO₂ incubator. After 24 h, the medium was replaced with fresh medium containing stationary phase transgenic promastigotes (2.5 X10^5 / 200 µL / well). Promastigotes invade the macrophage and are transformed into amastigotes. The test compounds were added at 2-fold dilutions in up to 7 points in fresh complete medium starting from a 100 µM concentration, and the plates were incubated at 37 °C in a CO₂ incubator for 72 h. After incubation, the drug containing medium was decanted and 50 µl phosphate-buffered saline (PBS) was added in each well and mixed with an equal volume of Steady-Glo luciferase assay substrate dissolved in Steady-Glo luciferase assay buffer. After gentle shaking for 1 to 2 min, the readings were recorded in a luminometer. The values were expressed as relative luminescence.

The IC₅₀ value of each compound was calculated by non-linear regression analysis of the concentration–response curve using the four-parameter Hill equations.

Cytotoxicity assay: The macrophage cell viability was determined using the MTT assay.⁴ Exponentially growing cells (J774) (1-2×10⁵ cells/100 µl/well) were incubated with test compounds. The test compounds are added at three fold dilutions up to 7 points in complete medium starting from 500 µM concentrations, and were incubated at 37 °C in a humidified mixture of CO₂ and 95 % air in an incubator. Control wells containing dimethyl sulfoxide (DMSO) without compounds were also included in the experiment. After incubation, 25 µL of MTT reagent (5 mg/mL) in PBS medium and incubated at 37 °C for 2 h. At the end of the incubation period, the supernatant were removed by inverting the plate completely without
disturbing cell layer and 150 µL of pure DMSO was added to each well. After 15 min. of shaking the readings were recorded as absorbance at 544 nm on a micro plate reader. The cytotoxic effect were expressed as 50 % lethal dose (i.e., as the concentration of a compound which provoked a 50 % reduction in cell viability compared to cell in culture medium alone). CC$_{50}$ values were estimated as described by Huber et al.$^5$ The selectivity index (SI) for each compound was calculated as the ratio between, cytotoxicity (CC$_{50}$) and activity (IC$_{50}$) against Leishmania amastigotes. Compounds with SI index > 5 were considered as safe in this cytotoxic assay.

**In vivo antileishmanial activity in hamster model:** The modified method was used for *in vivo* screening. Golden male hamsters (Inbred strain) weighing 40-45 gm were infected intra-cardially with $1 \times 10^7$ amastigotes per animal. Pre-treatment spleen biopsy of all the animals was carried out to assess the degree of infection on day 20$^{th}$ of infection. The animals with +1 infection (5-15 amastigotes/100 spleen cell nuclei) were included in the experiment. The infected animals were randomized into several groups of six animals each. Drug treatment by intraperitoneal route was initiated after 2 days of biopsy and continued for 5 consecutive days. Negative control group hamsters were administered 0.2 ml of saline solution. Post-treatment biopsies were done on day 7$^{th}$ and 28$^{th}$ day of the last drug administration and amastigote counts were assessed after Giemsa staining. Intensity of infection in both, treated and untreated animals, and also the initial count in treated animals was compared and the efficacy was expressed in terms of percent inhibition (PI) using the following formula:

$$PI = 100 - \frac{[ANAT \times 100]}{[INAT \times TIUC]}$$
Where PI is percent inhibition of amastigotes multiplication, ANAT is actual number of amastigotes in treated animals, INAT is initial number of amastigotes in treated animals and TIUC is times increase of parasites in untreated control animals.

**Experimental Section for Pharmacokinetics:**

**Material and methods:** The pharmacokinetics of 14t was studied in golden Syrian hamsters weighing 100 ± 10 gm. The hamsters were obtained from Laboratory Animal Division of the Institute and were housed in plastic cages under standard laboratory conditions with a regular 12 h day-night cycle. Suspension formulation containing 12.5 mg/ml of compound was prepared by triturating 14t, gum acacia (1%, w/v) and water (drop wise addition) in a mortar and pestle. A single 50 mg/kg oral dose was given to conscious hamsters using feeding needle and blood samples were withdrawn at various predefined times up to 24 h post dose. Serum samples were harvested from blood. All samples were stored at -80 °C until analysis. The serum (50 µL; blank, spiked or test) was extracted twice with 1 ml of extraction solvent (n-hexane: ethyl acetate, 60:40, % v/v) followed by vortex-mixing and centrifugation. The supernatant was evaporated to dryness in Turbovap LX (Caliper, Massachusetts, USA). The residue was reconstituted in 100 µL mobile phase and centrifuged. Clear supernatant (80 µL) was transferred into HPLC vials and 50 µL was injected on to the LC-MS/MS system.

A Shimadzu UFLC pump (LC-20AD) with online degasser (DGU-20A3), an auto-sampler (SIL-HTc) with a temperature-controlled peltier-tray and a API 4000 Q trap mass spectrometer (Applied Biosystems, Toronto, Canada) was used for analysis on a Discovery HS C-18 column (5 µm, 50 x 4.6 mm id) preceded with a guard column (5 µm, 20 x 4.0 mm, id) packed with the same material under isocratic condition at a flow rate of 0.7 mL/min. The mobile phase [85 % acetonitrile in aqueous ammonium acetate buffer (0.01 M)] was degassed by ultrasonication for
15 min before use. LC-MS/MS system was equilibrated for approximately 20 min before commencement of analysis. The column oven temperature was 40 °C. Total analysis time was 4 min per sample. Multiple reactions monitoring (MRM) was used to monitor the transitions m/z503.2 → 331.1 for 14t and m/z180.1 → 138.1 for phenacetin (Internal Standard) at 5500 V spray voltage. Data acquisition and quantitation were performed using analyst software (version 1.4.2; AB Sciex, Toronto, Canada). The method was linear over the concentration range of 1-200 ng/mL with recovery of >70 % and acceptable accuracy and precision.

References:

Supplementary Spectra of compounds:

$^1$H and $^{13}$C NMR spectra of 14a
$^1$H and $^{13}$C NMR spectra of 14b
$^1$H and $^{13}$C NMR spectra of 14c
$^{1}H$ and $^{13}C$ NMR spectra of 14d
$^1$H and $^{13}$C NMR spectra of 14e
$^1\text{H}$ and $^{13}\text{C}$ NMR spectra of 14f
$^1$H and $^{13}$C NMR spectra of 14g
$^1$H and $^{13}$C NMR spectra of 14h
$^1$H and $^{13}$C NMR spectra of 14i
$^1\text{H}$ and $^{13}\text{C}$ NMR spectra of 14j
$^1$H and $^{13}$C NMR spectra of 14k
$^1$H and $^{13}$C NMR spectra of 14l
$^1$H and $^{13}$C NMR spectra of 14m
$^1$H and $^{13}$C NMR spectra of 14n
$^{1}H$ and $^{13}C$ NMR spectra of 14o
$^1$H and $^{13}$C NMR spectra of 14p
$^1$H and $^{13}$C NMR spectra of 14q
$^1$H and $^{13}$C NMR spectra of 14r
\(^1\)H and \(^1^3\)C NMR spectra of 14s
$^1$H and $^{13}$C NMR spectra of 14t

![NMR Spectrum Image]
$^1$H and $^{13}$C NMR spectra of 14u